Escitalopram half-life
Escitalopram labeling and clinical pharmacokinetic review support a parent-drug half-life around 27 to 32 hours.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. The shaded band shows the reported half-life range. This is a mathematical visualization, not a personal concentration estimate.
Escitalopram: evidence and interpretation notes
Parent compound and treatment context
Escitalopram labeling and clinical pharmacokinetic review support a parent-drug half-life around 27 to 32 hours. A 30-hour center makes that range readable without converting it into treatment advice.
The plotted input is 30 hours for Escitalopram. It is a normalized comparison line, not a reconstruction of a measured blood concentration or a forecast of effects.
Escitalopram often needs steady-state and metabolite context, especially when doses repeat. This single-dose curve helps compare elimination speed but does not model treatment response, discontinuation symptoms, or medication changes.
What each source contributes
- DailyMed: ESCITALOPRAM TABLET, FILM COATED [BLUEPOINT LABORATORIES]. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
- PubChem: Escitalopram. This identity record confirms names and compound identity and does not supply a human half-life.
- The clinical pharmacokinetics of escitalopram. This human pharmacokinetic record adds measured route, analyte, and population context and does not become a universal result.
For Escitalopram, the numerical model is tied most closely to DailyMed: ESCITALOPRAM TABLET, FILM COATED [BLUEPOINT LABORATORIES]. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.
Why the range stays visible
The 27-to-32-hour range is retained beside the 30-hour input for Escitalopram. It is not an uncertainty slider or a personalized prediction; it shows that the cited literature does not reduce to one invariant value.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 30 h as a representative input for Escitalopram. In the simplified model, about 57.4% remains after 24 hours and about 3% remains after five half-lives, or roughly 6.3 days.
This is a day-scale half-life. Repeated exposure, timing, and source context start to matter more than a single snapshot of the curve. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
antidepressant context
Antidepressant half-life values often need source context because parent compounds, active metabolites, enzyme interactions, and steady-state timing can all matter.
- Half-life is not a treatment-response timeline.
- Active metabolites can make parent-compound curves incomplete.
- Stopping, tapering, switching, or combining medications requires qualified medical guidance.
ComparisonTimeline checkpoints and nearby profiles
Escitalopram timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 24 h | 57.4% | Meaningful modeled decline, not near-zero |
| 3.0 days | 18.9% | Long-tail portion of the model |
| 5.0 days | 6.25% | Low modeled remainder, not a clearance guarantee |
| 7.0 days | 2.06% | Low modeled remainder, not a clearance guarantee |
| 14 days | 0.04% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Escitalopram within the antidepressant group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Fluoxetine (4.0 days)
- Sertraline (26 h)
- Bupropion (21 h)
- Trazodone (7 h)
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 30 h |
|---|---|
| Reported range | 27 h to 32 h |
| Curve type | Normalized, first-order decline |
Selection note: Escitalopram labeling and clinical pharmacokinetic review support a parent-drug half-life around 27 to 32 hours. A 30-hour center makes that range readable without converting it into treatment advice.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: ESCITALOPRAM TABLET, FILM COATED [BLUEPOINT LABORATORIES].Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
- Identity record PubChem Compound Summary: Escitalopram.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
- Research abstract PubMed: The clinical pharmacokinetics of escitalopram.Direct pharmacokinetic context. Population, route, formulation, analyte, and sampling duration still determine how broadly the result can be applied.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the antidepressant group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.